Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line study of camrelizumab with or without apatinib versus platinum doublet chemotherapy in PD-L1-positive advanced or recurrent NSCLC
CTR20200637Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Sep 2020; status: active.
02
Drugs
camrelizumabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200637.